By Fineline Cube 
BioRay Pharmaceutical Co., Ltd. today announced the execution of a comprehensive license, supply, and commercialization agreement with Tabuk Pharmaceutical Manufacturing Company (Tabuk), a leading Saudi Arabian pharmaceutical firm. Under the terms, Tabuk will assume responsibility for regulatory registration and commercial roll‑out of BioRay’s biosimilar portfolio across multiple Middle East and North Africa (MENA) markets.
Agreement Highlights
- License & Supply – BioRay grants Tabuk exclusive rights to manufacture, distribute, and market its biosimilar products in the agreed‑upon MENA territories.
- Regulatory Stewardship – Tabuk will lead all registration dossiers, liaise with local authorities, and secure marketing authorizations for each product.
- Commercial Strategy – Joint commercial plans will leverage Tabuk’s established sales network and BioRay’s clinical data to accelerate market penetration.
Strategic Rationale
- Saudi Arabia’s Vision – The Kingdom’s per‑capita healthcare spending is the highest in the Middle East, and its population growth rate remains the fastest in the Gulf. Saudi policy now strongly encourages domestic biotechnology and biopharmaceutical development.
- Regional Expansion – The partnership positions BioRay to quickly scale its biosimilar offerings across a high‑growth region, while Tabuk gains access to a proven product pipeline that aligns with national health‑sector priorities.
- Competitive Edge – By combining BioRay’s clinical expertise with Tabuk’s regulatory and distribution capabilities, the alliance is poised to capture market share in a rapidly liberalizing MENA pharmaceutical landscape.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech